Rachel Yoder
Overview
Explore the profile of Rachel Yoder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoder R, Michaud A, Feagans A, Hinton-Froese K, Meyer A, Powers V, et al.
Int J Environ Res Public Health
. 2024 Apr;
21(4).
PMID: 38673415
Children with mental illness commonly live with caregivers who suffer from mental illness. Integrated mental-health-treatment approaches can provide more convenient and comprehensive care for families. This case report describes family-based...
2.
Martin M, Yoder R, Salgado R, Del Monte-Millan M, Alvarez E, Echavarria I, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2160-2169.
PMID: 38466643
Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs...
3.
Sharma P, Stecklein S, Yoder R, Staley J, Schwensen K, ODea A, et al.
JAMA Oncol
. 2023 Nov;
10(2):227-235.
PMID: 37991778
Importance: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not...
4.
Stecklein S, Kimler B, Yoder R, Schwensen K, Staley J, Khan Q, et al.
NPJ Breast Cancer
. 2023 Mar;
9(1):10.
PMID: 36878909
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant...
5.
Yoder R, Kimler B, Staley J, Schwensen K, Wang Y, Finke K, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):80.
PMID: 35817765
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression...
6.
Sharma P, Abramson V, ODea A, Nye L, Mayer I, Pathak H, et al.
Clin Cancer Res
. 2021 Feb;
27(14):3896-3904.
PMID: 33602685
Purpose: mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with...
7.
Sharma P, Kimler B, ODea A, Nye L, Wang Y, Yoder R, et al.
Clin Cancer Res
. 2020 Nov;
27(4):975-982.
PMID: 33208340
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of...
8.
Yoder R, Hulvershorn L, Ott C, Minshawi-Patterson N
J Child Adolesc Psychopharmacol
. 2020 May;
30(8):531-532.
PMID: 32392424
No abstract available.
9.
Mina A, Yoder R, Sharma P
Onco Targets Ther
. 2017 Oct;
10:4675-4685.
PMID: 29033586
Triple-negative breast cancer (TNBC) is an aggressive subtype associated with frequent recurrence and metastasis. Unlike hormone receptor-positive subtypes, treatment of TNBC is currently limited by the lack of clinically available...
10.
Bauer N, Yoder R, Carroll A, Downs S
J Dev Behav Pediatr
. 2016 Aug;
37(8):610-8.
PMID: 27541582
Objective: Pediatric anxiety is prevalent but frequently underdiagnosed compared with other behavioral conditions in primary care practice. Pediatricians routinely screen for attention-deficit hyperactivity disorder using the Vanderbilt Rating Scale, which...